Login to Your Account

Adds $8.5M in Venture Funding

Autifony Starts Phase I Work in Hearing Loss, Tinnitus

By Nuala Moran
Staff Writer

Wednesday, June 12, 2013
LONDON – Autifony Therapeutics Ltd. has started Phase I development of AUT00063, its treatment for age-related hearing loss and tinnitus, and raised a further £5.5 million (US$8.5 million) to take that lead program through to clinical proof of concept.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription